Focus: NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on metabolic diseases and neurology, with a pipeline spanning Type 2 Diabetes, liver disease, obesity, and oncology. Based in South San Francisco, the company operates as a mid-cap biotech with a diversified, multi-indication approach.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Promising early-to-mid stage pipeline in attractive markets, but recent layoffs and pre-revenue status create meaningful execution and financial stability risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for NGM Biopharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from NGM Biopharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent significant layoff is a red flag for financial stress, strategic reset, or failed partnership/financing; exercise due diligence on company stability and near-term funding.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo